GlassScriptPhysician profile
Marjorie A Garrett
NPI 1710955935
$7,180.98
in general payments reported to CMS, 2019-2025
28 companies · $948 in 2025
The $948 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,294 · 2020: $921 · 2021: $655 · 2022: $908 · 2023: $1,149 · 2024: $1,307 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,403 · Education: $0.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,403.12 |
| Education | $0.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,197.73 | 2019-2025 | Airsupra, Breztri, Bevespi Aerosphere |
| Lilly USA, LLC | $952.55 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $661.23 | 2021-2024 | |
| Novo Nordisk INC | $658.33 | 2019-2025 | Rybelsus, Ozempic |
| Alcon Vision LLC | $500.89 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $451.67 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $421.51 | 2022-2025 | Rexulti, Jynarque |
| Pfizer INC. | $391.02 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $283.77 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $278.00 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $267.45 | 2020-2024 | Arexvy, Shingrix |
| Exact Sciences Corporation | $194.97 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $143.16 | 2024-2025 | Austedo Xr, Austedo Xr |
| Allergan, INC. | $115.62 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.45 | 2024-2025 | Caplyta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $76.79 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $75.08 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $59.01 | 2019-2023 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.06 | 2022-2025 | Relistor, Xifaxan |
| Janssen Pharmaceuticals, INC | $48.65 | 2021-2025 | Spravato |
| Eisai INC. | $42.76 | 2020 | |
| Shield Therapeutics INC | $41.63 | 2023-2024 | Accrufer |
| Qiagen, LLC | $41.35 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $38.06 | 2025 | Opsumit, Uptravi |
| Vanda Pharmaceuticals INC. | $30.25 | 2025 | Fanapt |
| Abbott Laboratories | $23.07 | 2023 | Freestyle Libre 3 |
| Seqirus USA INC | $21.16 | 2025 | Flucelvax, Fluad |
| Idorsia Pharmaceuticals US INC | $17.76 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marjorie Garrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.